Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subperiosteal vs Loco-regional Articaine for Dental Implants
NCT01963754Phase 4
Key facts
- Status
- Unknown
- Start
- Apr 2017
- Primary completion
- Aug 2023
- Countries
- 1
- Sponsor
- Implantology Institute
- Modality
- Small Molecules
- Drugs
- articaine
01
Overview
Phase 4, randomised, double-blind trial of articaine (2 arms), sponsored by Implantology Institute. Primary endpoint: Anesthesia efficiency. Status: unknown.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Subepriosteal Articaine
Subperiosteal injection of Articaine 4% with 1:100,000 epinephrine.
Loco-regional Articaine
Loco-regional injection of Articaine 4% with 1:100,000 epinephrine.
03
Who it enrols
Patients requiring single unit implant rehabilitation in the posterior mandible with at least 6mm residual bone and keratinized tissue. Excludes smokers, drug addiction, local anesthetic allergy, hepatic disease, immunodepression, pregnancy, diabetes, and heart disease.
04
Endpoints
Primary
Anesthesia efficiency
Secondary
Intraoperatory Pain
Intraoperatory Anesthesia Complications
Post-Operatory Outcome Changes
Time of Surgery
Distance To Inferior Alveolar Nerve
Beyond the preview
Go deeper on NCT01963754.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01963754.